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ABSTRACT
The tumor suppressor, p53, plays critical roles in the
cell cycle progression, DNA repair and apoptosis.
The PIAS proteins (protein inhibitor of activated
STAT) were originally identified as inhibitors of the
JAK-STAT pathway. Subsequently, crosstalk
between the PIAS proteins and other signaling
pathways has been shown to be involved in various
cellular processes. Particularly, previous studies
have demonstrated that PIAS proteins regulate
p53-mediated transcription through sumoylation.
hZimp10, also named zmiz1, is a novel PIAS-like
protein and functions as a transcriptional
co-activator. We recently identified p53 to be
an hZimp10 interacting protein in the yeast two-
hybrid screen. The interaction between p53 and
hZimp10 was confirmed by GST pull-down and
co-immunoprecipitation assays. Co-localization of
p53 and hZimp10 proteins was also observed within
cell nuclei by immunostaining. Moreover, we show
that expression of exogenous hZimp10 enhances
the transcriptional activity of p53 and knockdown of
endogenous hZimp10 reduces the transcriptional
activity of p53. Furthermore, using chromatin immu-
noprecipitation assays, we demonstrate that
hZimp10 binds to p53 on the p21 promoter. Finally,
p53-mediated transcription is significantly impaired
in Zimp10 null embryonic fibroblasts. Taken
together, these results provide the first line of
evidence to demonstrate a role for Zimp10 in
regulating p53 function.
INTRODUCTION
The tumor suppressor protein p53 is a sequence-speciﬁc
DNA-binding transcription factor that regulates the cell
cycle checkpoint pathway in response to DNA damage
(1). The p53 gene is the most frequent target for genetic
alterations in cancer, with mutations occurring in  50%
of all human tumors (2,3). The tumor suppressor
functions of p53 are directly linked to its ability to control
the expression of gene products implicated in cell cycle
arrest and apoptosis (4,5). p53 binds as a tetramer to
speciﬁc response elements located in the transcriptional
control regions of p53 target genes, which initiates the
recruitment of other transcriptional co-regulators to
assemble a transcriptional complex that initiates RNA
synthesis (1,6). A broad spectrum of p53 downstream
target genes have been identiﬁed to be controlled by p53 in
a positive or negative manner (7). The fact that a variety
of pathways are mediated by these p53 target genes
demonstrates the role of p53 as an integrator of diverse
cellular signals.
The p53 protein contains two N-terminal activation
domains, a DNA-binding domain, and a C-terminal
oligomerization domain (1). The critical step for
p53-mediated transcriptional activation is facilitated by
the ability of p53 to simultaneously bind to speciﬁc DNA
sequences and recruit CBP/p300 and other transcriptional
co-regulators to p53-responsive promoters. CBP/p300
recruitment appears to concomitantly bring the general
transcription machinery, including TFIIB and TBP, and
RNA polymerase II to the target promoters (8,9).
Although a wealth of information exists concerning p53,
it is unclear about the actual mechanism by which this
critical tumor suppressor protein directly interacts with its
target genes and co-regulators to mediate its transcrip-
tional activity.
The PIAS proteins (protein inhibitor of activated
STAT) were ﬁrst identiﬁed as transcriptional co-regulators
of the JAK-STAT pathway (10). PIAS1 and PIAS3 can
inhibit the activity of STAT1 and STAT3, respectively
(11–13). Recent studies imply that the PIAS proteins may
play a role in chromatin modulation through sumoylation
(14,15). Sequence analysis indicates that the SUMO E3
ligase RING domain shares signiﬁcant homology with the
Miz domain of PIAS proteins (16). Several PIAS proteins,
such as PIASxa,x b, 1 and 3, have been shown to interact
with SUMO-1 and Ubc9 to sumoylate a variety of
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(17–23). Particularly, it has been shown that the transcrip-
tional activity of p53 can be regulated by PIAS through
sumoylation (24,25).
hZimp10 and hZimp7, also named zmiz1 and zmiz2,
respectively, are novel PIAS-like proteins that share a ring
ﬁnger domain, termed Miz (msx-interacting zinc ﬁnger),
with other PIAS proteins (26,27). This domain has been
shown to be important for PIAS-target protein interac-
tions and post-translational modiﬁcations (15). A novel
Drosophila gene, termed tonalli (tna), appears to be the
ortholog of hZimp7 and 10 (28). The protein encoded by
tna genetically interacts with the SWI2/SNF2 and
Mediator complexes, implying a potential role for the
hZimp proteins in transcription. To further explore their
roles in transcription, we performed a yeast two-hybrid
screen to seek out potential interacting proteins of hZimp7
and 10. Intriguingly, p53 was identiﬁed in the screen.
Using diﬀerent in vitro and in vivo approaches, we
demonstrated that hZimp10 physically interacts with the
p53 protein, and through the interaction hZimp10
augments p53-mediated transcription. These data eluci-
date a link between hZimp10 and p53 and demonstrate
that hZimp10 is a transcriptional co-regulator of p53.
MATERIALS AND METHODS
Yeasttwo-hybrid system
Yeast two-hybrid experiments were performed as
described previously (29). The DNA fragments containing
truncated hZimp10, hZimp7 or hLZTS2 were fused in
frame to the GAL4 DBD in the pGBKT7 vector
(CLONTECH Laboratories, Inc., Palo Alto, CA, USA).
Truncated p53 (amino acids: 251–383) was fused to the
GAL4 TAD in the pVP16 vector (CLONTECH). The
constructs were transformed into the modiﬁed yeast strain
PJ69-4A (30). Transformants were selected on Sabouraud
Dextrose medium lacking tryptophan, leucine and/or
adenine. The speciﬁcity of the interaction with p53 was
measured by a liquid b-galactosidase (b-gal) assay (29).
Recombinant DNAs
Full-length hZimp10 and hZimp7 cDNA was identiﬁed
and sub-cloned into pcDNA3-FLAG vector as described
previously (26,27). Subsequently, truncated mutants of
hZimp10 or hZimp7 were generated and sub-cloned
into the pGBKT7 vector containing a GAL4 DBD
for the yeast two-hybrid assay or into pGEX4T3 for
making GST fusion proteins. Truncated p53 (amino
acids: 251–383) was cloned into the pVP16 vector
containing the transcriptional activation domain
of VP16. Double-stranded oligonucleotides corresponding
to human hZimp7 (Z7-1: 50-GGACTGCATTATAAGC
CTAC-30, Z7-2: 50-GGACACCAGGACTACACACC-30,
and Z7-3: 50-GGTGGAGCAGACAGCTATCA-30) and
hZimp10 (Z10-1: 50-GGCCTCCATTACATCACAGT-30,
Z10-2: 50-GGCAGCAGCAGCAGTTCTCA-30 and
Z10-3:50-GGCACCAACTCCAACGACTA-30) were
cloned into the pBS/U6 vector to generate the short
hairpin RNA (shRNA) (31). Subsequently, the U6
promoter and the hZimp7 or hZimp10 shRNA sequences
were PCR ampliﬁed and transferred into the pLentiSuper
vector (Invitrogen, Carlsbad, CA, USA). The viral vector
was co-transfected with other packaging plasmids into
human embryonic kidney 293T cells for the virus
production (32). The pGL2hmdm-HX-Luc reporter was
a kind gift from Dr Moshe Oren (The Weizmann Institute
of Science, Israel). The p21-Luc reporter, pCMV-NEO-
Bam p53 and the p53-induced promoter/reporter PG13-
Luc were generously given by Dr Bert Vogelstein (Johns
Hopkins, Baltimore, MD, USA). The hZimp10 adenoviral
expression vector was cloned into the pAdTrack shuttle
vector (33). The plasmids were then cleaved with PmeI,
and transformed into BJ5183 cells that contain pAdEasy-1
vector. Adenoviral vectors were ampliﬁed in DH5a cells,
and propagated in HEK293 cells. Viral titers were
determined using plaque assays.
Cell cultures and transient transfections
The HCT116 p53
+/+ and HCT116 p53
 /  human colon
carcinoma cell lines are gifts from Dr Bert Vogelstein,
which were maintained in McCoy’s medium with
10% fetal bovine serum (FBS, HyClone Laboratories).
The SaOS-2 and U2OS cell lines are gifts of Dr Giannino
Del Sal (Laboratorio Nazionale C.I.B. Italy) and were
cultured in DMEM with 10% FBS. The human breast
cancer cell line, MCF7, and embryonic kidney cell line,
HEK293, were grown in 10% FBS-DMEM.
Transient transfections were carried out using
LipofectAMINE2000 (Invitrogen, Carlsbad, CA, USA).
Approximately 1.5 10
4 cells were seeded into a 48-well
plate 16h before transfection. Approximately 200ng of
total plasmid DNA per well were used in transfection.
Total cell lysates were collected 8–12h after transfection
and then luciferase and b-gal activities were measured in a
Monolight 3010 luminometer (Pharmingen, San Diego,
CA, USA). Luciferase activity was normalized by b-gal in
the same samples and reported as relative light units
(RLU). Individual transfection experiments were done in
triplicate and the results are reported as mean RLU ( SD)
from representative experiments.
GSTpull-down assay
Expression and puriﬁcation of GST fusion proteins were
performed as described previously (34). Equal amounts of
GST-fusion proteins coupled to glutathione sepharose
beads were incubated with MCF7 cell lysate at 48C for 2h
in binding buﬀer (20mM Tris-HCl-pH 7.8, 180mM KCl,
0.5mM EDTA, 5mM MgCl2, 0.5mM ZnCl2, 10%
glycerol, 0.1% NP-40, 0.05% dry non-fat milk, 1mM
DTT, 0.5mM PMSF). Beads were carefully washed three
times with binding buﬀer and then analyzed by
SDS-PAGE followed by western blot analysis using a
p53 antibody (DO-1: sc-126 Santa Cruz Biotechnology).
Cross-linking, immunoprecipitation and western blotting
The pcDNA3-HA-p53 with or without pcDNA3-FLAG-
hZimp10 vector was transfected into HEK293 cells. After
48h of transfection, cells were incubated with 0.5mM
dithio-bis (succinimidyl propionate) (DSP) in PBS to
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pH 7.6, and incubated with the same buﬀer for 5min to
neutralize DSP. The whole cell lysates were prepared as
described previously (26), and incubated with diﬀerent
antibodies at 48C with gentle rotation overnight. Then
equilibrated Protein-A Sepharose beads were added for
1.5h at 48C, and then collected. The beads were washed,
proteins eluted using 2  sample buﬀer (125mM Tris-HCl
pH 6.8, 4% SDS, 20% (v/v) glycerol, 0.004% bromphenol
blue), and analyzed by western blot. Detection was
performed with ECL reagents according to manufac-
turer’s protocol using ECL Hyperﬁlm (Amersham).
RNA isolation, RT-PCR andquantitative PCR assays
MCF7 cells were infected with either the hZimp10
expression adenovirus or a control virus in 5%
FBS-DMEM, then UV irradiated at 80J/m
2, and cultured
in the medium for 9h. Total RNA was then extracted
using RNAWiz RNA isolation reagent (Ambion, TX;
Cat#: 9736). The reverse transcription polymerase chain
reaction (RT-PCR) was carried out as described pre-
viously (35). In a 50ml PCR reaction, 1ml of cDNA
was ampliﬁed using 25 cycles of 45s at 948C, 30s at 618C
(for p21) or 508C (for GAPDH) and 30s at 728C. Primers
for p21 (50-ATGTCAGAACCGGCTGGGGAT-30;5 0-G
GAGTGGTAGAAATCTGTCATGC-30), mdm2 (50 –AT
GTGCAATACCAACATGTCTGTACC-30;5 0 –TTTGG
TCTAACCAGGGTCTCTTGT-30) and GAPDH (50-CC
ATGGAGAAGGCTGGGG-30;5 0-CAAAGTTGTCAT
GGATGACC-30) were used in the PCR reaction. For
quantitative PCR, cDNA samples were mixed with SYBR
qPCR Super Mix Universal (Invitrogen) and speciﬁc
primers in the MX 3005P thermocycler (Stratagene).
Relative mRNA levels were calculated from the point
where each curve crossed the threshold line as reported
previously (36,37). Reactions were done in triplicate
and the values were normalized by the GAPDH expres-
sion level.
Chromatin immunoprecipitation (ChIP) andre-ChIP assays
MCF7 or HEK293 cells were irradiated at 40J/m
2 using
a UV Stratalinker 1800 (Stratagene) and then incubated
at 378C for 6h. Subsequently, cells were treated with
DSP to cross-link protein complexes and washed with
Tris-wash buﬀer. After the last wash with PBS, cells
were treated with formaldehyde and subjected to ChIP
analysis as described previously (38). Brieﬂy, cells
were collected and washed sequentially with cold PBS,
Wash Buﬀer I (0.25% Triton X100, 10mM EDTA,
0.5mM EGTA and 10mM HEPES, pH 6.5), and Wash
Buﬀer II (200mM NaCl, 1mM EDTA, 0.5mM EGTA
and 10mM HEPES, pH 6.5). Cells were then lysed in
lysis buﬀer (1% SDS, 10mM EDTA, 50mM Tris pH 8.1
and protease inhibitors). The chromatin was sheared to
an average size of 800bp by sonication and diluted 10-fold
in ChIP dilution buﬀer (2mM EDTA, 150mM NaCl,
20mM Tris-HCl, pH 8.1, 1% Triton X-100), and then
subjected to immunoprecipitation with either an
anti-Zimp10 chicken antibody or anti-p53 antibody
(Santa Cruz) for overnight at 48C and recovered with
goat a IgY-agarose (Aves Labs) or Protein A Sepharose
(Amersham). The immunoprecipitates were serially
washed with diﬀerent TSE-based buﬀers and eluted for
PCR analysis. For re-ChIP, the immunocomplexes were
eluted with re-ChIP elution buﬀer (10mM DTT), and the
supernatant was diluted 1:40 in ChIP dilution buﬀer.
Antibodies against the second proteins of interest were
added, incubated at 48C overnight, and collected by
incubating with either goat anti-chicken IgYagarose or
protein-A beads at 48C for 2h. In both ChIP and re-ChIP
assays, the immuno-complexes were eluted from the beads
through incubation with 10X bead volume of elution
buﬀer (1% SDS, 0.1M NaHCO3). Cross-links were
reversed by incubating elution samples at 658C for
6h and chromatin fragments were puriﬁed with the PCR
Puriﬁcation Kit (Qiagen). ChIP and input DNA were
analyzed by PCR using p21 promoter-speciﬁc primers,
50-GTGGCTCTGATTGGCTTTCTG-30 and 50-CTGAA
AACAGGCAGCCCAAG-30, respectively (39,40). P21
PCR parameters were: 958C for 5min then 33 cycles of
958C for 30s, 608C for 30s and 728C for 20s. The samples
were also ampliﬁed with GAPDH primers, 50-CGGTG
CGTGCCCAGTTG-30 and 50-GCGACGCAAAAGAA
GATG-30, as controls (41).
Immunostaining
HEK293 cells were seeded overnight and synchronized
with 0.5mM mimosine (Sigma Chemical Co., St. Louis,
MO, USA) as described previously (42). Cells were
released from the mimosine block by washing three
times with PBS and incubating in fresh 10%
FBS-DMEM at 378C for 12h. Cells were ﬁxed with
4% paraformaldehyde and immunostained with either an
anti-Zimp10 or anti-p53 antibody followed by incubation
with species-speciﬁc Alexaﬂuor 488 and 594-conjugated
secondary antibodies. Images were analyzed by confocal
microscopy with 60  and 40  objectives.
Mouseembryonic fibroblasts
Mice heterozygous for a neomycin-disrupted allele of the
Zimp10 gene were mated, and embryos were harvested
from the females at embryonic day 9.5. Embryos were
isolated in cold PBS and digested with 250ml trypsin
(0.05%) as described previously (34). Cells were directly
plated into 48-well plates to adhere overnight, and used
for transient transfection assays. To determine MEF
genotype, embryo sacs isolated during the dissection
were digested, genomic DNA was extracted, and the
wild-type or mutant Zimp10 alleles were determined by
PCR with speciﬁc primers.
RESULTS
Identification of p53as apotential hZimp10 interacting
protein
Using a bait construct containing the N-terminal region of
hZimp7 (amino acids: 1–643), which is also highly
conserved in hZimp10, we employed a modiﬁed yeast
two-hybrid system to identify proteins that potentially
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7
transformants, 123 grew under selective conditions and
showed increased adenine and b-gal production in
medium. Rescue of the plasmids and sequencing of the
inserts revealed several diﬀerent cDNAs. Most of them
were transcriptional factors and PIAS proteins. Among
these clones, a cDNA encoding the tumor suppressor p53,
between amino acids 251 and 383, was identiﬁed.
Since hZimp7 and hZimp10 share signiﬁcant sequence
similarity, we co-transformed the p53 clone with various
constructs containing either GAL-DBD alone or the
fusion proteins with the N-terminal fragment of hZimp7
(1–643 amino acids), and diﬀerent truncations of hZimp10
(Figure 1A–C). The original bait construct, pGBKT7-
hZimp7 (1–643aa), showed a speciﬁc interaction with
pVP16-p53 (251–383aa) (Figure 1D). Interestingly,
the construct containing the fragment of hZimp10
between amino acids 451–753 appeared to interact
with the pVP16-p53 as well. The above results provide
the ﬁrst line of evidence to demonstrate an interaction
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Figure 1. Speciﬁc interaction between hZimp10 and p53. (A) and (B): The cDNA fragments containing diﬀerent portions of human Zimp7, Zimp10
or human LZTS2 were fused to the GAL4-DBD in the pGBKT7 vector. Numbers correspond to amino acid residues. (C) A schematic representation
of the yeast two-hybrid assay for mapping the interaction between p53, hZimp7 and hZimp10 proteins. (D) The pVP16-p53 containing the fusion
protein of VP16-TAD and p53 (251–383) were co-transformed with pGBKT7 vector alone or diﬀerent pGBKT7 fusion constructs. In addition,
pVP16-AR (1–333) was included as a positive control, for the pGBKT7-hZimp10 (451–753). Transformed cells were plated on SD-Ade-Leu-Trp
plates, and SD-Leu-Trp plates to monitor transformation eﬃciency. Three independent colonies were inoculated from each transformation
experiment for subsequent liquid b-gal assays. The data for the liquid b-gal assays are shown as the mean S.D.
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protein p53.
hZimp10 interacts withp53 in vitroand in vivo
The interactions between hZimp7 and hZimp10 with p53
were further assessed by GST pull-down experiments.
Truncated hZimp7, hZimp10 and the PIAS1 SAP
(Scaﬀold attachment factor, Acinus and PIAS) and MIZ
domains were cloned in frame to generate GST fusion
proteins. They were expressed upon IPTG induction
and equalized on a SDS–PAGE gel with comassie
blue staining (Figure 2A). MCF7 cell lysates were
applied to each sample, which was immobilized onto a
glutathione-sepharose matrix for the binding assay. The
elutions from the above samples were analyzed by
SDS-PAGE and western blot with a p53 antibody.
PIAS1 and Zimp proteins contain a conserved Miz
domain that shares similar sequences with the ring ﬁnger
domain of MDM2 (24). Therefore, we tested whether the
Miz domains of PIAS1 and Zimp10 interact with p53.
Intriguingly, only a weak interaction was observed
between the Miz domains and endogenous p53 proteins
(Figure 2A). In addition to the Miz domain, the SAP
(Scaﬀold attachment factor A/B, Acinus and PIAS)
domain has also been shown to be involved in protein–
protein interactions (43). Thus, we included it in our
binding assays, although only slight binding activity above
background was observed with this construct. Notably,
the GST-fusion construct containing amino acids 451–753
of hZimp10 showed the strongest binding activity with
p53. Since this region only covers a small portion of the
Miz domain, this result suggests that the Miz domain of
hZimp10 may not be required for the interaction with p53.
In addition, the GST-fusion protein containing the N-
terminal fragment of hZimp7 also showed an interaction
with p53, which is consistent with the yeast two-hybrid
results. Taken together, the above results show that the
regions spanning hZimp10 amino acids 451 to 753 and
hZimp7 amino acids 1–643 are mainly responsible for
binding to p53.
To conﬁrm that hZimp10 interacts with p53 in intact
cells, co-immunoprecipitation assays were carried out
to detect potential protein complexes. Initially, we
co-transfected FLAG-tagged hZimp10 with a p53 expres-
sion vector in HEK293 cells (Figure 2B). Whole cell
lysates containing FLAG-hZimp10 and p53 proteins were
immunoprecipitated with normal mouse IgG or a anti-p53
antibody. As shown in Figure 2C, Flag-hZimp10 proteins
were only detected in the p53 immunoprecipitate but not
in normal IgG immunoprecipitate. These data indicate
that p53 can form a protein complex with hZimp10 in
intact cells.
Next, we further evaluated the interaction between
endogenous hZimp10 and p53 proteins in HEK293 cells.
With speciﬁc antibodies against p53 and hZimp10, we
detected the expression of both proteins in HEK293 cells
(Figure 2D). Immunoprecipitation of the whole cell lysates
with ahomemade hZimp10 antibody (26) revealed thatp53
forms a protein complex with hZimp10, which provides
evidence to demonstrate that hZimp10 and p53 interact
endogenously.
hZimp10 augments p53-mediated transcription
Since hZimp7 and 10 have been shown to act as transcrip-
tional co-activators (26,27,34,44), we tested whether these
Zimp proteins regulate p53-mediated transcription.
p53
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Figure 2. Physical interaction between hZimp10 and p53 in vitro and in
intact cells. (A) Equal amounts of GST-PIAS1 MIZ domain,
GST-PIAS1 SAP domain, GST-hZimp10 MIZ (728–809 amino
acids), GST-hZimp10 Central (451–753 amino acids), GST-
hZimp10N-terminal (1–333 amino acids) and hZimp7N-terminal
(1–643 amino acids) fusion proteins were used to pull down
endogenous p53 in MCF7 cells. GST protein alone was used as a
negative control. Equal amounts of the above GST proteins were
analyzed on SDS-PAGE. Material bound to GST columns was
subjected to SDS-PAGE and western blot with p53-speciﬁc antibody.
(B) HEK293 cells were transfected with pcDNA3-HA-p53 (0.1mg) and
pcDNA3-FLAG-tagged hZimp10 (1.8mg). Here, 7.5% of the total
lysate volume (input) was probed with anti-FLAG antibody or anti-p53
antibody. (C) Cell lysates were then immunoprecipitated with the anti-
p53 antibody or normal IgG, and analyzed on SDS-PAGE by Flag
antibody or p53 antibody. (D) Five percent of the initial lysate volume
(input) or Zimp10 and IgG immunoprecipitates were analyzed by
western blot using either hZimp10 or p53 antibody.
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genous p53, we chose p53-null cells for these experiments.
A luciferase reporter driven by the MDM2 promoter
(MDM2-Luc) was co-transfected with plasmids expressing
p53, hZimp7 and hZimp10 into HCT116 p53
 /  colon
cancer cells in various combinations (Figure 3A).
An approximate 2-fold increase of p53-mediated tran-
scriptional activity above the baseline was observed when
cells were transfected with 0.4ng of p53 expression vector.
The p53 activity was further increased  7- or 9-fold in the
presence of 40 or 80ng of hZimp10, respectively, above
the baseline. In contrast, co-transfection of hZimp7
showed no signiﬁcant eﬀect (Figure 3A), which is
consistent with the yeast two-hybrid and GST pull-down
assays that showed only a weak interaction between p53
and hZimp7. There was no eﬀect when hZimp7 or
hZimp10 were transfected alone with the reporter plasmid,
indicating that the Zimp10-mediated induction in reporter
activity was indeed through p53 (Figure 3A). To conﬁrm
our ﬁndings, we repeated the transient transfection assay
in SaOS2 osteosarcoma cells, another p53 negative cell
line. A similar augmentation of hZimp10 on p53-mediated
transcription was observed on the MDM2 promoter/
reporter (Figure 3B). Moreover, we evaluated the eﬀect of
hZimp10 on p21 promoter, another downstream target
of p53. A similar enhancement by hZimp10 was observed
on p21 promoter in HCT116 p53
 /  and SaOS2 cells
(Figure 3C and D). These results provide evidence to
demonstrate that hZimp10 augments p53-mediated
transcription.
To investigate the eﬀect of hZimp10 in regulating the
transcriptional activity of endogenous p53, MCF7 cells,
which possess wild-type p53, were infected with either
hZimp10 expression adenoviruses or control GFP viruses,
and treated with or without UV irradiation. The
endogenous transcripts of the p53 target gene, p21, were
then measured by semi-quantitative RT-PCR. The level
of p21 transcript showed no signiﬁcant change in cells
in the absence of UV treatment (Figure 3E). However,
in cells treated with UV irradiation, the level of
p21 transcript was increased  1-fold in cells with
ectopically expressed hZimp10 in comparison with the
cells infected with GFP control viruses. The enhancement
of hZimp10 on p53-meidated transcription in MCF7 cells
was further evaluated by quantitative PCR assays. As
shown in Figure 3F, the levels of MDM2 and p21
transcripts were higher in cells expressed exogenous
hZimp10 proteins than control cells (P50.05). These
results support our initial observation in the transient
transfection experiments, and further demonstrate a
functional role for hZimp10 in augmenting p53-mediated
transcription.
Endogenous Zimp10 isrequired forp53-mediated
transcriptionin vivo
Next, we extended our study to investigate the involve-
ment of endogenous hZimp10 in regulating the transcrip-
tional activity of p53. We ﬁrst generated three short
hairpin RNA (shRNA) constructs for hZimp10 (31) and
tested their knockdown eﬀects on ectopically expressed
hZimp10 in CV1 cells. All three hZimp10 shRNA
constructs reduced the expression of FLAG-tagged
hZimp10 protein (Figure 4A). However, there was no
change in tubulin expression in the same samples. The
hZimp10 shRNA construct 2 appeared most eﬀective in
the knockdown experiment using overexpressed hZimp10
and also signiﬁcantly reduced the expression of endogen-
ous hZimp10 protein in HEK293 cells (Figure 4B).
In addition, we evaluated the speciﬁcity of shRNA vectors
for hZimp7 and hZimp10 in MCF7 cells. As shown
in Figure 4C and D, the shRNA vectors speciﬁc for
hZimp7 or hZimp10 showed selective knockdown for their
respective targets. In HCT116 p53
+/+ cells, the hZimp10
shRNA construct selectively reduced hZimp10 enhance-
ment of p53-mediated transcription (Figure 4E), which is
consistent with the western blot results. Moreover,
knockdown of endogenous hZimp10 expression by the
hZimp10 shRNA vector in MCF7 cells resulted in a 5-fold
reduction in p53-mediated transcription on both the
p21-Luc and MDM2-Luc reporters (Figure 4F and G).
In contrast, there was no change in p53 transcriptional
activity in samples transfected with hZimp7 shRNA
constructs. Using quantitative PCR assays, we further
assessed the suppressive eﬀect of the hZimp10 shRNA
on the expression of endogenous p21 and MDM2
transcripts. The levels of p21 and MDM2 mRNAs were
reduced in cells infected with hZimp10 shRNA-2 lenti-
viruses whereas cells either infected with the control
viruses or hZimp7 shRNA viruses showed no eﬀect
(Figure 4H). Taken together, the above data indicate
that endogenous hZimp10, but not hZimp7, plays an
important role in the augmentation of p53-mediated
transcription.
To further demonstrate the role of hZimp10 in a more
biologically relevant setting, we have recently generated
mice in which the Zimp10 gene locus has been disrupted
by replacing exons 8–10 with a neomycin resistance
cassette. The phenotype of this disruption is embryonic
lethality at approximately E10.5 (Beliakoﬀ et al., unpub-
lished data). To determine whether endogenous Zimp10
regulates p53-mediated transcription, we generated mouse
embryo ﬁbroblasts (MEFs) from E9.5day embryos and
transfected them with the p53-responsive MDM2-Luc and
pG13-Luc reporters (45). As shown in Figure 4I,  4-fold
induction of luciferase activity by ectopically expressed
p53 on either MDM2 or pG13 promoters, respectively,
was observed in MEFs prepared from wild-type embryos
(Zimp10
+/+). In contrast, no activity was observed in
MEFs where both Zimp10 alleles were disrupted
(Zimp10
 / ). These data demonstrate a crucial role for
endogenous Zimp10 in the regulation of p53-mediated
transcription in vivo.
p53 and hZimp10 co-localize in thenucleus
To examine whether a dynamic interaction between p53
and hZimp10 exists in cells, we detected the cellular
distribution of both endogenous p53 and hZimp10
proteins using speciﬁc antibodies. HEK293 cells were
synchronized by adding 0.5mM mimosine overnight. Cells
were then washed three times with PBS and stimulated
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Figure 3. hZimp10 augments p53-mediated transcription. (A) HCT116 p53
 /  cells were transiently transfected in 48-well plates with 100ng of
MDM2-Luc, 25ng of pSV40-b-gal, 0.4ng of pCMV-p53, and where indicated, 40 or 80ng of pcDNA3-FLAG-hZimp7 or pcDNA3-FLAG-hZimp10.
The total amount of plasmid per well was normalized in all transfections by addition of pcDNA3 empty vector. Luciferase activity is reported as
relative light units and represented as mean SD. (B) SaOS2 cells were transiently transfected in 48 wells as described above. (C) and (D) Transient
transfection assays were performed in HCT116 p53
 /  and SaOS2 cells with the p21-Luc reporter cells, respectively. (E) MCF7 cells were infected
with either the hZimp10 expression adenovirus or a control virus, and then UV irradiated at 80J/m
2 as indicated. Semi-quantitative RT-PCR with
p21 or GAPDH primers was performed on the total RNA isolated from each sample. PCR products were subjected to electrophoresis on a 5%
acrylamide gel. The bar graph is a representation of the band intensity measured by densitometry. (F) Quantitative RT-PCR assays were performed
to detect the levels of p21 and MDM2 transcripts in MCF cells that were either the hZimp10 expression adenovirus or a control virus. The detailed
experimental procedures were described in the Materials and Methods section.
Nucleic Acids Research, 2007, Vol. 35, No. 13 4529with full medium for 12h (42). As shown in Figure 5A,
both p53 and Zimp10 proteins show a strong nuclear
distribution in human HEK293 cells, which is consistent
with previous reports (26,46,47). Intriguingly, a signiﬁcant
amount of overlay between endogenous p53 and hZimp10
proteins was observed in these cells. Based on these
observations, we conclude that hZimp10 can co-localize
with p53 in the nucleus, where the proteins may form a
ternary transcriptional complex.
To demonstrate the direct involvement of hZimp10 to
coordinate p53-mediated transcription, chromatin
immunoprecipitation (ChIP) assays were performed to
detect the occupancy of hZimp10 on p53-regulated
promoters. HEK293 cells were grown in DMEM with
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Figure 4. Knockdown of hZimp10 expression reduces p53 transcription. (A) CV1 cells were transfected with 2mg of pcDNA3-FLAG-hZimp10
(F-hZ10) and 200ng of diﬀerent pBS/U6-hZimp10-shRNA constructs (Z1, Z2 and Z3), or PBS/U6 vector only in 6-well plates. Whole cell lysates
were prepared after 48h of transfection, and analyzed by western blotting with either FLAG or Tubulin antibody. (B) Diﬀerent hZimp10 shRNA
constructs or PBS/U6 vector were transfected into HEK293 cells. Cells were harvested and cell lysates were analyzed as described in (A). (C) and (D)
CV1 cells were transfected with 2mg of pcDNA3-FLAG-hZimp10 or pcDNA3-FLAG-hZimp7 (F-hZ7) in the presence of 200ng either hZimp10 or
hZimp7 shRNA constructs as indicated in the ﬁgure to check for knockdown speciﬁcity. (E) Luciferase and b-gal activities were measured in whole
cell lysates as described above. HCT116 p53
+/+ or MCF7 cells were stably infected with either control lentivirus, hZimp7 shRNA lentivirus or
hZimp10 shRNA lentivirus and transfected in 48-well plates with 100ng of MDM2-Luc or 100ng p21-Luc, 25ng of pSV40-b-gal, 40ng of pcDNA3-
FLAG-hZimp10 or pcDNA3-FLAG-hZimp7. (H) The levels of p21 and MDM2 transcripts were assessed by quantitative RT-PCR assays in MCF
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4530 Nucleic Acids Research, 2007, Vol. 35, No. 135% FBS. Soluble chromatin was prepared after formal-
dehyde treatment of the cell cultures, and speciﬁc
antibodies against hZimp10 were used to immunoprecipi-
tate hZimp10-bound genomic DNA fragments. The
genomic DNA was analyzed by PCR using speciﬁc pairs
of primers spanning the p53-binding sites in the p21
promoter (Figure 5B). Both p53 and hZimp10 recruitment
was detected within the region of the p21 promoter that
contains a functional p53-binding site (40) in HEK293
cells after UV treatment. As the average length of the
genomic DNA fragments produced in these experiments
was  800bp (data not shown), we could not distinguish
with certainty whether the occupancy of hZimp10 on the
p21 promoter is through an interaction with p53 or
through interactions with other DNA-binding proteins.
Therefore, we performed re-ChIP assays to assess the
relationship between p53 and hZimp10 on the p21
promoter (Figure 5C). Using the hZimp10-speciﬁc anti-
body, we re-immunoprecipitated the elutions from the
immunoprecipitates with a p53 antibody or normal IgG.
As shown in Figure 5D, the presence of hZimp10 on the
p21 promoter was selectively detected in the immunopre-
cipitates using the p53 antibody but not the IgG control.
In addition, the samples re-immunoprecipitated with anti-
hZimp10 showed a more intense p21 promoter PCR
fragment than the ones using normal IgY. These data
suggest that the recruitment of hZimp10 onto the p21
promoter is mediated through p53.
DISCUSSION
The p53 tumor suppressor is a DNA sequence-speciﬁc
transcriptional factor that is mutated in  50% of human
tumors (3). In response to a variety of cellular signals,
perhaps the most well studied is its DNA damage
function. p53 regulates the transcription of numerous
genes involved in diﬀerent cellular processes, including cell
cycle arrest and cell death. Like other transcriptional
factors, the transcriptional activity of p53 is largely
dependent on its ability to recognize and bind speciﬁc
DNA sequences and to recruit other necessary transcrip-
tional co-regulators. In recent years, numerous transcrip-
tion co-regulators have been shown to either directly or
indirectly interact with p53 to modulate its transcriptional
activity. For instance, physical and functional interactions
between p53, p300 and HAT proteins have been well
documented (48,49). The involvement of PRMT1 and
CARM1 methyltransferases has also been demonstrated
in previous studies (50). Importantly, p53 has been shown
to facilitate formation of a preinitiation complex via direct
interactions with the components of the general transcrip-
tion complex (51). The experiments reported here
Input
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Figure 5. p53 and hZimp10 co-localize with each other in the nucleus and form a ternary transcriptional complex. (A) HEK293 cells were
synchronized with 0.5mM mimosine in culture media for 24h, washed three times with PBS and incubated with fresh media for 12 additional hours.
Cells are immunostained with either a chicken antihuman Zimp10 or anti-p53 antibody followed by incubation with species-speciﬁc Alexaﬂuor 488
and 594-conjugated secondary antibodies, respectively. Images were analyzed by confocal microscopy with 60  and 40  objectives. (B) HEK293
cells were seeded on three 10cm dishes at 85% conﬂuency and allowed to adhere overnight. The cells were UV irradiated at 40J/m
2 UV, cross-linked
with DSP (1.6mM), then cross-linked with 1% formaldehyde before chicken anti-human Zimp10, IgY, mouse anti-human p53, or mouse IgG
antibody were added to immunoprecipitate chromatin. Primers speciﬁc to the distal p53 responsive element on the p21 promoter ( 2301) were used
to PCR amplify the eluted chromatin. Primers speciﬁc to GAPDH were used as a control to monitor immunoprecipitation speciﬁcity. (C) Schematic
representation of ChIP and re-ChIP procedure. (D) HEK293 cells were prepared as described in (A) and mouse anti-human p53 or mouse IgG
antibody was added to immunoprecipitate chromatin. The elution was subjected to a second immunoprecipitation by chicken antihuman Zimp10 or
IgY antibody. The ﬁnal elution was analyzed by p21 promoter-speciﬁc primers as described in (B).
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p53 and hZimp10, a novel PIAS-like protein (26). The
interaction was ﬁrst identiﬁed by a modiﬁed yeast two-
hybrid screen. Using GST pull-down and immunopreci-
pitation assays, we then show that p53 binds to hZimp10
both in vitro and in intact cells. Moreover, immunoﬂuor-
escence assays demonstrated that p53 co-localizes with
hZimp10 within cell nuclei. Furthermore, analysis of the
interaction by ChIP (chromatin immunoprecipitation
assay) on the promoter of the p21 gene, a downstream
target of p53, showed that hZimp10 is involved in the
p53-mediated transcriptional complex. Taken together,
these multiple lines of evidence clearly indicate that p53
and hZimp10 can speciﬁcally interact in a biologically
relevant manner.
To search for the biological consequence of the
interaction between p53 and hZimp10, we performed a
series of experiments to assess the eﬀect of hZimp10 on
p53-mediated transcription. As shown in this article,
hZimp10 acts as a transcriptional co-activator to augment
p53-mediated transcription. We observed that expression
of exogenous hZimp10 or knockdown of endogenous
hZimp10 aﬀects p53-mediated transcription on both the
p21 and Mdm2 promoters. Introducing exogenous
hZimp10 into MCF7 cells also augments endogenous
p53-mediated transcription by increasing p21 transcript
levels. Interestingly, hZimp10 consistently up-regulates
p53-mediated transcriptional activity in all cell contexts
examined to date. This result is consistent with the
observation that hZimp10 harbors a strong intrinsic
transactivation domain within its C-terminus (26). It
appears that through this domain hZimp10 can act as a
transcriptional co-activator to augment p53-mediated
transcription, which is consistent with previous observa-
tions showing that hZimp10 functions as a transcriptional
co-activator of the androgen receptor and Smad3 (26,34).
It has been shown that the transcriptional activity of
p53 can be regulated by multiple post-translational
modiﬁcations, including phosphorylation, ubiquitination
and acetylation (52). In addition, p53 can also be
covalently modiﬁed by sumoylation, which is mainly
regulated through SUMO-1 (Small Ubiquitin-related
Modiﬁer 1) (53,54). Recent studies have shown that
PIAS proteins can bind to, sumoylate, and inﬂuence the
activity of p53 (22,25). In particular, PIAS1 and PIASxb
act as E3 ligases to enhance sumoylation of p53 in vivo and
in vitro (24). Although it has been shown that PIAS
proteins negatively regulate the transcriptional activity of
p53 through sumoylation, recent data indicated that
PIAS1 and PIAS3 may function as activators of
p53-dependent gene expression (22). Previously, we have
shown that Zimp10 co-localizes with the AR and SUMO-
1at replication foci and enhances AR sumoylation.
However, the mechanism for hZimp10-mediated enhance-
ment of p53 activity appears to be through a sumoylation-
independent pathway because over-expression of hZimp10
and SUMO-1 in HEK293 cells showed no eﬀect on
sumoylation of the p53 protein (Supplementary Data).
In addition, our results indicate that the hZimp10-
mediated enhancement of p53 activity may be at least
partially Miz domain-independent because the strongest
interaction was observed with a hZimp10 region contain-
ing only a portion of the Miz sequence (Figure 2A).
Recently, we have demonstrated that both hZimp7 and
hZimp10 enhance the transcriptional activity of several
transcriptional factors (26,27,34,44). However, the precise
mechanism(s) for these Zimp proteins in transcriptional
regulation still remains unclear. Our previous data
showing that hZimp10 co-localizes with newly synthesized
DNA at replication foci throughout S phase suggest
that hZimp10 may play an important role in both
chromatin assembly and maintenance of chromatin (26).
Intriguingly, a homolog of human Zimp proteins, termed
tonalli (tna), has been identiﬁed in Drosophila and was
shown to genetically interact with SWI2/SNF2 and the
Mediator complexes in complementation studies (28).
In addition, we have shown previously that the C-terminal
proline-rich domains of hZimp7 and 10 possess signiﬁcant
intrinsic transcriptional activity (26,27), and through these
domains, the Zimp proteins can enhance transcription
both in trans and in cis. The ﬁnding that hZimp10
augments p53-mediated transcription is consistent with
our previous studies showing that hZimp10 functions as a
transcriptional co-activator of the androgen receptor and
Smad3/Smad4 (26,34). Interestingly, the C-terminal pro-
line-rich region is not found in other PIAS or PIAS-like
proteins, suggesting that the Miz domain family may
consist of distinct groups of proteins that contain unique
structures and play distinct roles in regulating transcrip-
tion and other cellular processes. Therefore, it is
conceivable that although hZimp10 and other PIAS
proteins interact with p53 physically, they may regulate
the function of p53 through diﬀerent mechanisms. Indeed,
this is in agreement with our results suggesting that the
Miz domain is generally dispensable for the hZimp10–p53
interaction while published reports suggest that the Miz
domain is important for PIAS–p53 interactions (25).
hZimp7 and hZimp10 share signiﬁcant sequence simi-
larity, particularly within their C-terminal regions (27).
Both proteins contain an intrinsic transactivation domain
and function as transcriptional co-activators (26,27).
These two Zimp proteins show diﬀerent tissue distribution
proﬁles, which may suggest unique roles for these proteins
in regulating diﬀerent target genes. Our recent data
showing that disruption of the Zimp10 gene in mice
results in embryonic lethality at approximately E10.5
suggest that hZimp7 and 10 are not functionally
redundant. In this study, even though we observed that
hZimp7 interacts with p53 in a yeast two-hybrid assay, it
showed no interaction between the two intact proteins in
immunoprecipitation assays (see Supplementary Data).
In addition, we only observed a very weak eﬀect of
hZimp7 on p53-mediated transcription. These data
suggest that hZimp7 and hZimp10 proteins, although
structurally similar, likely play a diﬀerent role in
p53-mediated transcription.
In this study, we also assessed the interaction between
hZimp10 and p53 in Zimp10 null cells. Using MEFs
generated from Zimp10 knockout mice, we demonstrated
that the disruption of Zimp10 inhibits p53-mediated
transcription. In MEFs with an intact wild-type Zimp10
allele, a clear dose-dependent induction of p53
4532 Nucleic Acids Research, 2007, Vol. 35, No. 13transcriptional activity was observed in cells transfected
with increasing amounts of p53. In contrast, no enhance-
ment was observed in cells where both Zimp10 alleles were
disrupted. This perhaps provides the most convincing
evidence that Zimp10 can indeed regulate p53 activity in
an in vivo system. Further study using this in vivo system
should help to elucidate the biological inﬂuence of Zimp10
on p53-mediated tumor repressive eﬀects.
In conclusion, this study demonstrates for the ﬁrst time
that hZimp10, a novel PIAS-like protein, augments the
transcriptional activity of the p53 tumor suppressor. This
interaction provides an additional line of evidence to
demonstrate that Zimp10 is involved in transcriptional
regulation. Further studies into the molecular mechanisms
by which hZimp10 and other PIAS proteins regulate
p53-mediated transcription may provide new insight into
the biological role of PIAS and PIAS-like proteins in cell
growth, apoptosis, diﬀerentiation and tumorigenesis.
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Supplementary Data are available at NAR Online.
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